• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
By KEVIN CURRAN Aug 22, 2018 | 07:24 PM EDT
Stocks quotes in this article: MRK, PFE, JNJ

Some of the biggest drug makers in America are choosing to keep prices in check to avoid federal intervention on its pricing structures.

According to a Health and Human Services report compiled by a senior advisor to the secretary for drug price reform, a threat to act on prices was sufficient enough for the industry to clean up its own act.

The research report states that there have been 60% fewer brand drug price increases from May 11 to August 15 this year than in the prior year. Furthermore, there were 54% more decreases in the same comparative periods.

HHS secretary Alex Azar was not naive enough to believe that the industry is cutting prices out of kindness to their fellow man.

"As the President said, there have been some really significant moves, because the drug companies and others in the system see the writing on the wall," he said in a cabinet meeting published by the White House on August 16. "The system is going to change, prices will come down, and they are skating [to] where the puck is going to be."

Azar also reported that 15 major companies have signaled their intention to make announcements regarding control over their drug pricing, calling Merck & Co. (MRK) and Pfizer Inc. (PFE) out by name.

However, Merck actually pre-empted the report's release by announcing its plan to pursue "responsible pricing" initiatives in July, pledging to not increase their net portfolio of drugs by more than the rate of inflation.

"They're trying to all get better at self-policing," Vamil Divan, senior research analyst at Credit Suisse told Real Money. "Merck, Pfizer, and Johnson & Johnson (JNJ) are definitely all vigilant on [pricing]."

Divan noted that Merck in the past year actually decreased its net portfolio cost overall in 2017, indicating it was not a problem even before President Trump's "blueprint" for drug cost reduction.

Divan said he thinks the industry can control itself, out of its own self-interest, making major pharmaceutical companies still highly investable.

For example, he indicated his own buy rating for Merck, which he stated still has much room to grow, with key drug approvals like KEYTRUDA coming just recently.

To be sure, a decrease in drug prices is sure to affect the margin of drug manufacturers. However, at the moment, drug companies are prepared to sacrifice margin to save autonomy in their industry.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing

More from Investing

Traders: Keep Your Fingers on the Trigger and Targets on a Bottom

James "Rev Shark" DePorre
Mar 4, 2021 4:39 PM EST

As the correction goes on, here's what to do now.

There's Nothing Pleasant About the Current Action

Timothy Collins
Mar 4, 2021 3:00 PM EST

The next good sized bounce in SPAC names, and maybe ARKK names, might be the last exit off the bagholder highway.

Royal Caribbean Is Getting Called Back to Port

Bruce Kamich
Mar 4, 2021 3:00 PM EST

Has the reopening news already been priced in? The charts are telling investors to look out ahead.

Nike's Charts and Indicators Are Still Bearish

Bruce Kamich
Mar 4, 2021 2:20 PM EST

Avoid the long side.

Listen to Mr. Market, Not Mr. Powell

Jim Collins
Mar 4, 2021 1:56 PM EST

Let's look at bonds, rates and, especially, inflation for a true picture of what's going on, and where to put your money.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login